Trial
NCT04760288
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Medullary Thyroid Cancer
Intervention
Pralsetinib
Why stopped
Due to several logistical challenges during start-up which could not be overcome study was withdrawn.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-01-05